Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADAM17 shRNA
- Development stage
- Preclinical
- Lead developer
- University of Bonn
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
ADAM17 shRNA is a short hairpin RNA designed to silence the expression of the **ADAM17** (A Disintegrin and Metalloproteinase 17) gene, also known as **TACE** (TNF-alpha converting enzyme). In the context of high-grade gliomas, ADAM17 is involved in the ectodomain shedding of Kit ligand (Kitl/SCF), which promotes tumor cell migration and invasion. By knocking down ADAM17 using RNA interference (RNAi), researchers observed significantly reduced glioma cell migration and inhibited Kitl shedding in stable transfectants of glioma cell lines such as LN-229, LN-308, and U87-MG. This tool is primarily utilized in preclinical research to investigate the functional role of ADAM17 in cancer progression, signaling pathways, and invasive behavior.
- Other names
- ADAM17-specific short hairpin RNAADAM-17-specific short hairpin RNAADAM 17-specific short hairpin RNAshADAM17shADAM-17shADAM 17ADAM17-specific shRNAADAM-17-specific shRNAADAM 17-specific shRNA
02
Targets
ADAM17 (A disintegrin and metalloprotease 17)
Beyond the preview
Go deeper on ADAM17 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADAM17 shRNA.